| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,724 | 2,748 | 08.06. | |
| 2,730 | 2,740 | 06.06. |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | Valneva's Chikungunya Vaccine Advances With Pediatric Trial, Phase 3 In 2026 | ||
| Do | Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ | IXCHIQ® was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV)Antibody levels remained high after six months in both dose groups,... ► Artikel lesen | |
| Do | [Valneva SE] Declaration of shares and voting rights - May 2025 | ||
| Mi | Valneva SE - 6-K, Report of foreign issuer | ||
| Mi | Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update | Saint-Herblain (France), June 4, 2025 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company ("the Company"), today announced the availability of documentation for its Combined... ► Artikel lesen |
